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Introduction
Non-Hodgkin lymphoma (NHL) accounts for 4% of all cancers1 and resulted in
an estimated 199,700 deaths worldwide in 2012.2 NHL subtypes include diffuse
large B-cell lymphoma (DLBCL; 22-36% of cases of NHL), mantle cell lymphoma
(MCL; 1%-14% of cases of NHL), and follicular lymphoma (FL; 8%-32% of cases
Activation of the phosphatidylinositol 3-kinase/mechanistic targetof rapamycin pathway plays a role in the pathogenesis of non-Hodgkin lymphoma. This multicenter, open-label phase 2 study
evaluated buparlisib (BKM120), a pan-class I phosphatidylinositol 3-
kinase inhibitor, in patients with relapsed or refractory non-Hodgkin
lymphoma. Three separate cohorts of patients (with diffuse large B-cell
lymphoma, mantle cell lymphoma, or follicular lymphoma) received
buparlisib 100 mg once daily until progression, intolerance, or withdraw-
al of consent. The primary endpoint was overall response rate based on
a 6-month best overall response by cohort; secondary endpoints included
progression-free survival, duration of response, overall survival, safety,
and tolerability. Overall, 72 patients (26 with diffuse large B-cell lym-
phoma, 22 with mantle cell lymphoma, and 24 with follicular lym-
phoma) were treated. The overall response rates were 11.5%, 22.7%,
and 25.0% in patients with diffuse large B-cell lymphoma, mantle cell
lymphoma, and follicular lymphoma, respectively; two patients (one
each with diffuse large B-cell lymphoma and mantle cell lymphoma)
achieved a complete response. The most frequently reported (>20%)
adverse events of any grade in the population in which safety was stud-
ied were hyperglycemia, fatigue, and nausea (36.1% each), depression
(29.2%), diarrhea (27.8%), and anxiety (25.0%). The most common
grade 3/4 adverse events included hyperglycemia (11.1%) and neutrope-
nia (5.6%). Buparlisib showed activity in relapsed or refractory non-
Hodgkin lymphoma, with disease stabilization and sustained tumor bur-
den reduction in some patients, and acceptable toxicity. Development of
mechanism-based combination regimens with buparlisib is warranted.
(This study was funded by Novartis Pharmaceuticals Corporation and
registered with ClinicalTrials.gov number, NCT01693614). 
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ABSTRACT
of NHL).3-5 Response to treatment is heterogeneous due to
the varying biology of each NHL subtype; disease course
can be indolent or aggressive.6,7 The 5-year survival rate
from 2006 to 2012 was 62% for patients with DLBCL,
56% for those with MCL, and 88% for those with FL.5
Combining rituximab, a monoclonal antibody targeting
the CD20 antigen on B cells, with standard chemothera-
py has improved NHL treatment outcomes.8 Despite high
response rates to rituximab-based regimens, many
patients become resistant to treatment or relapse after ini-
tially achieving a response.8
Phosphatidylinositol 3-kinase (PI3K)/mechanistic target
of rapamycin (mTOR) signaling regulates many cellular
activities, including proliferation, survival, angiogenesis,
and glucose metabolism.9 Due to its effects on B-cell sig-
naling, dysregulation of PI3K signaling is associated with
cancer development and may play a key role in the patho-
genesis of NHL.10-14 Class I PI3K, the most common forms
implicated in cancer, are heterodimers with regulatory
(p85) and catalytic (p110) subunits.15 There are four class
I isoform catalytic subunits, p110α, p110b, p110γ, and
p110d (encoded by PIK3CA, PIK3CB, PIK3CG, and
PIK3CD, respectively),15 with varying levels of expres-
sion; p110α and p110b are ubiquitous, whereas p110γ
and p110d are mainly expressed in hematopoietic cells.15,16
Preclinical evidence indicates that B-cell malignancies fre-
quently overexpress PIK3CD.17,18 The PI3Kd inhibitor ide-
lalisib showed antitumor activity in patients with
relapsed or refractory indolent NHL,19,20 and was subse-
quently approved in 2014 for the treatment of patients
with relapsed FL and chronic lymphocytic leukemia (in
the latter case in combination with rituximab).21,22
Differential PI3K isoform expression levels have also
been associated with different disease stages in NHL.23
For example, in MCL, PIK3CA expression increased upon
progression and was implicated as an escape mechanism
for PI3Kd inhibition.14,23 Other members of the PI3K path-
way, including the phosphatase and tensin homolog
(PTEN; a negative regulator of PI3K activity) and mTOR
(a downstream effector), also play a role in NHL.14,24 Thus,
treating patients with a targeted drug that can inhibit all
four isoforms of PI3K may help to block escape path-
ways, prolong responses, and improve outcomes com-
pared to those achieved with treatment with an inhibitor
specific for a single isoform, particularly in patients with
relapsed or refractory disease.25,26 Buparlisib, a potent, oral
pan-PI3K inhibitor, showed antitumor activity in lym-
phoma cell lines, induced apoptosis in DLBCL27 and
reduced myc-dependent proliferation in MCL,28 showed
preclinical activity in hematologic malignancies,28,29 and
had clinical efficacy in solid tumors, including breast can-
cer.30-33 In this open-label phase 2 study, we evaluated the
efficacy and safety of buparlisib in patients with relapsed
or refractory DLBCL, MCL, or FL.
Methods
Patients
Adult patients (aged ≥18 years) were eligible if they had his-
tologically confirmed DLBCL, MCL, or FL that had relapsed or
was refractory to one or more prior therapies. Patients were
required to have one or more measurable nodal lesions (≥2 cm
according to International Working Group criteria);34,35 if no such
nodal lesion was present at baseline, one or more measurable
extra-nodal lesions were required. Additional inclusion criteria
included an Eastern Cooperative Oncology Group performance
status of ≤2, adequate bone marrow and organ function, and
fasting plasma glucose ≤120 mg/dL. Patients with DLBCL were
either ineligible for autologous or allogeneic stem cell transplan-
tation or had previously received a transplant.
Patients previously treated with PI3K inhibitors, or those with
evidence of graft-versus-host disease, active or past central nerv-
ous system disease, poorly controlled diabetes mellitus (glycated
hemoglobin >8%), active cardiac disease, a history of myocar-
dial infarction within 6 months, or documented congestive heart
failure or cardiomyopathy were excluded (additional informa-
tion is available in the Online Supplementary Methods). Patients
were excluded if they had received anticancer therapy within 4
weeks (6 weeks for nitrosourea, monoclonal antibodies, or mit-
omycin-C) prior to starting the study.
Objectives
The primary objective was to determine the overall response
rate, defined as the proportion of patients with a best overall
response of complete or partial response, according to
International Working Group criteria,34,35 in three different histo-
logical subgroups of NHL (i.e., DLBCL, MCL, and FL). The pri-
mary objective was assessed locally, per investigator, independ-
ently for each cohort, and was based on a 6-month best overall
response. Secondary objectives were to assess progression-free
survival, duration of response, overall survival, and safety and
tolerability in the three histological subgroups (additional infor-
mation is available in the Online Supplementary Methods). 
Study design
This was a multicenter, open-label, single-arm, phase II study
in patients with relapsed or refractory NHL (NCT01693614).
Patients with previously treated DLBCL, MCL, or FL received
buparlisib 100 mg daily continuously in 28-day cycles until dis-
ease progression, death, or intolerable toxicity. Treatment inter-
ruptions due to toxicity lasting ≥28 days required permanent
study drug discontinuation. Up to two dose reductions (to 80 mg
or 60 mg daily) were allowed; patients needing additional reduc-
tions discontinued the study. 
Patients provided written informed consent prior to entering
the study. The study protocol and informed consent form were
reviewed and approved by the independent ethics committee or
institutional review board for each center. The study was con-
ducted in accordance with the International Conference on
Harmonization Guidelines for Good Clinical Practice, with
applicable local regulations, and with the ethical principles of
the Declaration of Helsinki. 
Schedule of assessments
The assessment schedule is described in the Online
Supplementary Methods.
Statistical analyses
The intent-to-treat population included all patients who
received one or more dose of study treatment; the safety set
included all patients who received one or more dose of study
treatment and had one or more post-baseline safety assess-
ments. The analysis for each cohort (i.e., DLBCL, MCL, and FL)
was based on an exact binomial test comparing the overall
response rate to a reference level of 10% in the intent-to-treat
population, with a significance level of 5% (two-sided). An exact
95% Clopper-Pearson confidence interval (CI) for the overall
response rate was calculated. Time-to-event endpoints (i.e., pro-
gression-free survival, duration of response, and overall survival)
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were described using Kaplan–Meier curves with associated sum-
mary statistics. For progression-free survival and duration of
response, patients not known to have progressed or who died
by the data cut-off date were censored at the time of last tumor
assessment or before any further anticancer therapy had been
given. For overall survival, patients not known to have died at
the data cut-off were censored at the date of their last contact




Between February 28, 2013, and June 15, 2014, 72
patients were enrolled in the trial, including 26 with
DLBCL, 22 with MCL, and 24 with FL (Table 1). Their
median age was 65 years (range, 28-85) and 68.1% were
male. Most patients (73.6%) had stage III/IV disease at ini-
tial diagnosis, and 36.1% of patients had elevated lactate
dehydrogenase levels. All patients had received prior anti-
neoplastic therapy, and 17 patients (23.6%) had under-
gone a prior autologous stem cell transplantation (6 with
DLBCL, 7 with MCL, and 4 with FL). The median number
of prior antineoplastic regimens was three (range, 1-12) for
patients with DLBCL, two (range, 1-6) for patients with
MCL, and two (range, 1-9) for patients with FL. The most
frequently received prior antineoplastic therapy was an
alkylating agent (n=70; 97.2%), followed by rituximab
(n=68; 94.4%), anthracycline (n=60; 83.3%), and ben-
damustine (n=21; 29.2%). At last treatment, a best
response of complete or partial response was achieved by
11 patients with DLBCL (42.3%; 15.4% complete
responses and 26.9% partial responses), 13 with MCL
(59.1%; 31.8% complete responses and 27.3% partial
responses), and 13 with FL (54.2%; 41.7% complete
responses and 12.5% partial responses): ten (38.5%), four
(18.2%), and four (16.7%) patients, respectively, had
refractory disease.
The most common reasons for discontinuing prior ther-
apy were completion of the prescribed regimen (n=36;
50.0%), disease progression (n=24; 33.3%), and adverse
events (n=5; 6.9%); other reasons were listed as
“unknown” or “other”. The date of data cut-off was
February 25, 2015 for all analyses, except for the analysis
of best overall response, which occurred separately in
each cohort when all patients within the cohort had
received 6 months of treatment.
Table 1. Baseline characteristics and patient disposition of the patients.
                                                     DLBCL             MCL               FL        All patients
                                                    (n = 26)          (n = 22)       (n = 24)     (N = 72)
Baseline characteristics
Median age, years (range)            64 (28-81)         69 (47-79)     61 (41-85)    65 (28-85)
Male, n (%)                                        18 (69.2)           18 (81.8)        13 (54.2)      49 (68.1)
Stage at last assessment prior to study entry, n (%)                                                 
I/II                                                       10 (38.5)             1 (4.5)           7 (29.2)       18 (25.0)
III/IV                                                   16 (61.5)           20 (90.9)        17 (70.8)      53 (73.6)
Missing                                                     0                     1 (4.5)                 0               1 (1.4)
Bulky disease                                      5 (19.2)              1 (4.5)           4 (16.7)       10 (13.9)
Elevated LDH                                     11 (42.3)            6 (27.3)          9 (37.5)       26 (36.1)
Prior bone marrow involvement    6 (23.1)            13 (59.1)        15 (62.5)      34 (47.2)
Median number of prior                 3 (1-12)              2 (1-6)            2 (1-9)         2 (1-12)
regimens (range)
Prior therapies, n (%)                                                                                                        
Alkylating agent                                26 (100)            22 (100)        22 (91.7)      70 (97.2)
Rituximab*                                       25 (96.2)           20 (90.9)        23 (95.8)      68 (94.4)
Anthracycline                                   26 (100)            19 (86.4)        15 (62.5)      60 (83.3)
Bendamustine                                  3 (11.5)             6 (27.3)         12 (50.0)      21 (29.2)
Purines                                                1 (3.8)               2 (9.1)            1 (4.2)          4 (5.6)
Radiotherapy                                    9 (34.6)             3 (13.6)          6 (25.0)       18 (25.0)
Autologous SCT                                6 (23.1)             7 (31.8)          4 (16.7)       17 (23.6)
Best response at last treatment, n (%)                                                                         
Complete response                        4 (15.4)             7 (31.8)         10 (41.7)      21 (29.2)
Partial response                              7 (26.9)             6 (27.3)          3 (12.5)       16 (22.2)
Stable disease                                   2 (7.7)              3 (13.6)          5 (20.8)       10 (13.9)
Progressive disease                      10 (38.5)            4 (18.2)          4 (16.7)       18 (25.0)
Other†                                                 3 (11.5)              2 (9.1)            2 (8.3)          7 (9.7)
WHO/ECOG performance status, n (%)                                                                        
0                                                           9 (34.6)            10 (45.5)        17 (70.8)      36 (50.0)
1                                                          14 (53.8)           12 (54.5)         6 (25.0)       32 (44.4)
2                                                           3 (11.5)                   0                 1 (4.2)          4 (5.6)
Patients’ disposition‡
Treatment disposition, n (%)                                                                                           
Treatment ongoing                           2 (7.7)              5 (22.7)           2 (8.3)         9 (12.5)
End of treatment                            24 (92.3)           17 (77.3)        22 (91.7)      63 (87.5)
Primary reason for treatment cessation, n (%)                                                          
Disease progression                     11 (42.3)            5 (22.7)          7 (29.2)       23 (31.9)
Adverse events                                 6 (23.1)             9 (40.9)          4 (16.7)       19 (26.4)
Protocol deviation                           5 (19.2)              2 (9.1)                 0               7 (9.7)
Physician’s decision                         1 (3.8)               1 (4.5)           4 (16.7)         6 (8.3)
Patient withdrew consent                   0                          0                5 (20.8)         5 (6.9)
Patient/guardian decision                    0                          0                 2 (8.3)          2 (2.8)
Death                                                   1 (3.8)                    0                      0               1 (1.4)
Autologous SCT: autologous stem cell transplant; DLBCL: diffuse large B-cell lymphoma; ECOG:
Eastern Cooperative Oncology Group; FL: follicular lymphoma; LDH: lactate dehydrogenase;
MCL: mantle cell lymphoma; WHO: World Health Organization. *In the FL cohort, one patient
who did not receive rituximab and two patients who did receive rituximab also received prior
investigational anti-CD20 therapy. †Other includes unconfirmed complete response (n=1,
DLBCL; n=0, MCL and FL), unknown (n=2, DLBCL; n=1, MCL and FL), and not applicable (n=0,
DLBLC; n=1, MCL and FL).‡The date of data cut-off was February 25, 2015.
Table 2. Best overall response.
                                         DLBCL (n = 26)     MCL (n = 22)     FL (n = 24)
Best overall response at 6 months,* n (%) [95% CI]
Complete response                     1 (3.8)                     1 (4.5)                       0
Partial response                            2 (7.7)                    4 (18.2)               6 (25.0)
Stable disease                              5 (19.2)                  13 (59.1)             15 (62.5)
Progressive disease                   12 (46.2)                   2 (9.1)                 1 (4.2)
Unknown†                                       6 (23.1)                    2 (9.1)                 2 (8.3)
Overall response rate‡               3 (11.5)§                  5 (22.7)               6 (25.0)
                                                       [2.5, 30.2]               [7.8, 45.4]           [9.8, 46.7]
Disease control rate||                   8 (30.8)                  18 (81.8)             21 (87.5)
                                                       [14.3, 51.8]             [59.7, 94.8]         [67.6, 97.3]
CI: confidence interval; CR, complete response; DLBCL: diffuse large B-cell lymphoma;
FL: follicular lymphoma; MCL: mantle cell lymphoma; *Data cut-off for best overall
response had a 6-month primary analysis cut-off that corresponded to June 19, 2014,
for the DLBCL cohort, February 25, 2015, for the MCL cohort, and August 7, 2014, for the
FL cohort. †Reasons for unknown best overall response: no valid post-baseline assess-
ment (n=7; 4 DLBCL, 2 FL, 1 MCL), all post-baseline assessments were not evaluable for
response (n=2, 1 DLBCL, 1 MCL), stable disease too early (n=1, DLBCL). ‡Defined as
complete response or partial response. §Of 26 patients with DLBCL, 16 patients had a
clinical response (i.e., complete response, partial response or stable disease) to the
last therapy prior to study entry; the overall response rate for these patients was 6.3%
(1 patient achieved a partial response) ||Defined as stable disease or complete
response or partial response. 
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Efficacy
Overall response rate
The overall response rates in the DLBCL, MCL, and FL
cohorts were 11.5% (95% CI: 2.5-30.2), 22.7% (95% CI:
7.8-45.4), and 25.0% (95% CI: 9.8-46.7), respectively
(Table 2). The primary endpoint was not met, since none
of the cohorts reached the minimum number of responses
to establish a 35% response rate required for statistical sig-
nificance at the 5% level, based on the lower limits of the
95% CI (i.e., the 95% CI lower bound was <10% for all
three cohorts). As shown in waterfall plots of the best
overall response during buparlisib treatment, evaluable
patients in all three cohorts had a reduction in investiga-
tor-assessed tumor size (Figure 1A-C). The disease control
rates in the DLBCL, MCL, and FL cohorts were 30.8%
(95% CI: 14.3-51.8), 81.8% (95% CI: 59.7-94.8), and
87.5% (95% CI: 67.6-97.3), respectively. 
Time to response and duration of response
For the patients in the DLBCL cohort who responded,
the median time to response was 2.1 months (range, 1.8-
3.5) and the median duration of response was 2.2 months
(95% CI: 1.2-not estimable). Of the three patients who
responded, two relapsed. In the MCL cohort, the median
time to response was 1.8 months (range, 0.9-9.4), while
the median duration of response was not reached; of the
five patients who responded, one patient subsequently
relapsed. In the FL cohort, the median time to response
and duration of response were 3.5 months (range, 1.6-5.9)
and 11.0 months (95% CI: 3.9-not estimable), respective-
ly; of the six patients who responded, two relapsed.
Progression-free survival
The median progression-free survival of patients with
DLBCL, MCL, and FL was 1.8 months (95% CI: 1.5-4.0),
11.3 months (95% CI: 3.8-not estimable), and 9.8 months
(95% CI: 3.8-not estimable), respectively (Figure 2A). The
estimated 6-month progression-free survival rate was
12.6% (95% CI: 2.3-32.0) in the DLBCL cohort, 68.6%
(95% CI: 39.8-85.7) in the MCL cohort, and 60.7% (95%
CI: 31.7-80.6) in the FL cohort. The median follow-up time
for progression-free survival was 1.7, 4.7, and 3.7 months
for the DLBCL, MCL, and FL cohorts, respectively.
Overall survival
With a median follow-up time of 4.6 months, the medi-
an overall survival for the DLBCL cohort was 5.2 months
(95% CI: 3.1-not estimable) (Figure 2B). For the MCL and
FL cohorts the median follow-up time for overall survival
was 8.2 months and 12.1 months, respectively, and the
median overall survival was not reached for either cohort. 
Safety
The median duration of exposure to buparlisib in the
DLBCL, MCL, and FL cohorts was 7.5 weeks (range, 1.7-
76.0), 20.6 weeks (range, 1.7-54.1), and 16.3 weeks (range,
3.3-81.3), respectively. As of the data cut-off, 47 patients
(65.0%; 50.0%, 68.2%, and 79.2% in the DLBCL, MCL,
and FL cohorts, respectively) had received buparlisib for
≥8 weeks and 21 patients (29.2%; 7.7%, 45.5%, and
37.5%, in the DLBCL, MCL, and FL cohorts, respectively)
had received the drug for ≥24 weeks. Treatment was
ongoing as of February 25, 2015, the data cut-off date, in
nine patients (12.5%), including two with DLBCL, five
Buparlisib in patients with NHL: CBKM120Z2302
haematologica | 2017; 102(12) 2107
Figure 1. Best overall response with respect to best percentage change from
baseline in investigator-assessed tumor size during buparlisib therapy for
patients with measurable lesions divided by cohort The graphs include
patients with measurable disease at baseline and ≥1 subsequent tumor
assessments. The data cut-off was February 25, 2015, for all cohorts. (A)
Patients with DLBCL (n=20), (B) patients with MCL (n=20), (C) patients with FL
(n=22). Best overall response is indicated for each patient. Note that for two
patients with DLBCL, the post-baseline assessment was not evaluable or best
overall response was progressive disease due to a new lesion (asterisk). The
dashed line shows the percentage change that represents the criterion for
response, according to International Working Group criteria.34,35 CR: complete
response; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; IWG:
International Working Group; MCL: mantle cell lymphoma; PD: progressive dis-




with MCL, and two with FL. The remaining 63 patients
(87.5%) had discontinued treatment (Table 1). The most
common primary reasons for treatment discontinuation
were disease progression (n=23; 31.9%) and adverse
events (n=19; 26.4%).  
Of the 22 patients (30.6%; DLBCL, n=7; MCL, n=7; FL,
n=8) who required a dose reduction, the majority required
only one dose reduction (54.5%: DLBCL, 4/7; MCL, 2/7;
FL, 6/8), while only one patient in the FL cohort required
≥3 dose reductions (Online Supplementary Table S1). Of the
patients requiring a dose reduction, all patients required a
dose reduction due to adverse events (n=22: DLBCL, n=7;
MCL, n=7; FL, n=8), and one patient in the FL cohort had
an additional dose reduction due to a dosing error. The
median percent of days with the full dose was 100%
(range, 14.3-100%), 100% (range, 6.6-100%), and 97.4%
(range, 4.2-100%) for patients in the DLBCL, MCL, and FL
cohorts, respectively. Dose interruptions occurred in 36
patients (50.0%): 11 with DLBCL, 10 with MCL, and 15
with FL. Among patients whose dosing was interrupted,
A. Younes et al.
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Figure 2. Kaplan–Meier curves for progres-
sion-free survival and overall survival.
Kaplan–Meier curves for the secondary end-
points by cohort (DLBCL, MCL, and FL) are
shown here together, but the curves are not
meant to be compared between cohorts as
the study was not designed to compare the
three cohorts. (A) Progression-free survival
curves; median follow-up time: DLBCL, 1.7
months; MCL, 4.7 months; FL, 3.7 months.
(B) Overall survival curves; median follow-up
time: DLBCL, 4.6 months; MCL, 8.2 months;
FL, 12.1 months. CI, confidence interval;
DLBCL, diffuse large B-cell lymphoma; FL,
follicular lymphoma; MCL, mantle cell lym-
phoma; NE, not estimable; OS, overall sur-
vival; PFS, progression-free survival.
A
B
the reasons for the dose interruption included adverse
events [n=32 (88.9%): DLBCL, n=11; MCL, n=9; FL,
n=12], scheduling conflict [n=5 (13.9%): MCL, n=2; FL,
n=3], and dosing error [n=4 (11.1%): MCL, n=1; FL, n=3].
The most common adverse events (occurring in >3
patients) that caused dose reduction or interruption were
hyperglycemia (n=8), fatigue (n=6), and nausea (n=4).
Hyperglycemia, fatigue, and nausea (n=26; 36.1% each),
depression (n=21; 29.2%), diarrhea (n=20; 27.8%), and
anxiety (n=18; 25.0%) were the most frequently reported
adverse events of any grade, regardless of their relation-
ship with the study drug, occurring in >20% of patients
(Table 3). The most frequently reported grade 3/4 adverse
events, regardless of study drug relationship (occurring in
≥3 patients), were hyperglycemia (n=8; 11.1%), neutrope-
nia (n=4; 5.6%), fatigue, nausea, anxiety, asthenia, confu-
sional state, and thrombocytopenia (each n=3; 4.2%).
Mood disturbances (e.g., anxiety, agitation, confusional
state, depression, stress, psychiatric decompensation) of
any grade were reported in 29 patients (40.3%); 24
patients (33.3%) had grade 1/2 mood disorders, and five
patients (6.9%) had grade 3/4 mood disorders. Laboratory
hematologic and biochemical abnormalities of any grade
were reported in 63 patients (87.5%) and 71 patients
(98.6%), respectively (Table 3). Grade 3/4 hematologic
and biochemical abnormalities occurring in more than
10% of patients were lymphocytopenia (n=16; 22.2%),
hyperglycemia (n=15; 20.8%), and neutropenia (n=9;
12.5%) (Table 3). Grade 3/4 infections were reported in
four patients with DLBCL, four patients with MCL, and
Buparlisib in patients with NHL: CBKM120Z2302
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                                                       Most common adverse events, n (%)
                                                                    All patients (n = 72)
                                                                                    
                                                            All                                  Grade
                                                         grades                                3/4
Any-cause adverse events (occurring in >5% of all patients) 
Fatigue                                                     26 (36.1)                                   3 (4.2)
Hyperglycemia                                        26 (36.1)                                  8 (11.1)
Nausea                                                     26 (36.1)                                   3 (4.2)
Depression                                              21 (29.2)                                   2 (2.8)
Diarrhea                                                   20 (27.8)                                         0
Anxiety                                                      18 (25.0)                                   3 (4.2)
Decreased appetite                              14 (19.4)                                   1 (1.4)
Weight decrease                                    13 (18.1)                                         0
Asthenia                                                   11 (15.3)                                   3 (4.2)
Constipation                                            11 (15.3)                                         0
Cough                                                       10 (13.9)                                         0
Abdominal pain                                        8 (11.1)                                    1 (1.4)
Pruritus                                                     8 (11.1)                                          0
Rash                                                           8 (11.1)                                    1 (1.4)
Vomiting                                                    8 (11.1)                                          0
Dyspepsia                                                  7 (9.7)                                      1 (1.4)
Dyspnea                                                     7 (9.7)                                      2 (2.8)
Tremor                                                        7 (9.7)                                      1 (1.4)
Headache                                                   6 (8.3)                                      1 (1.4)
Pyrexia                                                        6 (8.3)                                           0
Urinary tract infection                            6 (8.3)                                      2 (2.8)
Agitation                                                     5 (6.9)                                           0
Anemia                                                        5 (6.9)                                      2 (2.8)
Back pain                                                    5 (6.9)                                           0
Confusional state                                     5 (6.9)                                      3 (4.2)
Insomnia                                                    5 (6.9)                                           0
Muscle spasms                                        5 (6.9)                                           0
Thrombocytopenia                                  5 (6.9)                                      3 (4.2)
Vertigo                                                        5 (6.9)                                      2 (2.8)
Dizziness                                                    4 (5.6)                                           0
Dry skin                                                      4 (5.6)                                           0
Hypokalemia                                              4 (5.6)                                      1 (1.4)
Neutropenia                                              4 (5.6)                                      4 (5.6)
Pain in extremity                                      4 (5.6)                                      1 (1.4)
Pleural effusion                                        4 (5.6)                                      1 (1.4)
Hematologic abnormalities 
Anemia                                                     43 (59.7)                                   2 (2.8)
Thrombocytopenia                                36 (50.0)                                   3 (4.2)
Lymphocytopenia                                   31 (43.1)                                 16 (22.2)
Leukopenia                                              22 (30.6)                                   6 (8.3)
Neutropenia                                            19 (26.4)                                  9 (12.5)
Lymphocytosis                                        17 (23.6)                                   3 (4.2)
Biochemical abnormalities (occurring in >10% of all
patients)
Hyperglycemia                                        51 (70.8)                                 15 (20.8)
Increased AST                                        31 (43.1)                                   1 (1.4)
Hypercholesterolemia                          28 (38.9)                                         0
Hypertriglyceridemia                            28 (38.9)                                         0
Increased AP                                           27 (37.5)                                         0
Increased GGT                                       23 (31.9)                                   6 (8.3)
Increased creatinine                            19 (26.4)                                         0
Hyponatremia                                         19 (26.4)                                   3 (4.2)
Hypokalemia                                           18 (25.0)                                   2 (2.8)
Increased ALT                                         18 (25.0)                                   1 (1.4)
Hypophosphatemia                               16 (22.2)                                   3 (4.2)
Hypoalbuminemia                                  14 (19.4)                                         0
Hyperkalemia                                          12 (16.7)                                         0
Uric acid                                                   12 (16.7)                                   1 (1.4)
Hypernatremia                                       10 (13.9)                                         0
Hyperbilirubinemia                               10 (13.9)                                         0
Increased lipase                                     9 (12.5)                                          0
ALT: alanine aminotransferase; AP: alkaline phosphatase; AST: aspartate aminotrans-
ferase; GGT: gamma-glutamyl transferase.
                                                       Most common adverse events, n (%)
                                                                    All patients (n = 72)
                                                                                    
                                                            All                                  Grade
                                                         grades                                3/4
Table 3. Most frequently reported adverse events and laboratory abnormalities, regardless of relationship with the study drug.
one patient with FL. Of these, serious infections were
reported in two patients with DLBCL (pneumonia and uri-
nary tract infection), two patients with MCL (pneumonia
and septic shock), and one patient with FL (lung infection).
Treatment for patients who had infectious complications
was at the discretion of the investigator. 
Serious adverse events, regardless of a relationship with
the study medication, of any grade and grade 3/4 were
reported in 30 patients (41.7%: DLBCL, n=12; MCL, n=12;
FL, n=6) and 26 patients (36.1%: DLBCL, n=10; MCL,
n=12; FL, n=4), respectively. The most common serious
adverse events were confusional state (n=3), pleural effu-
sion (n=3), nausea (n=2), vomiting (n=2), dysphagia (n=2),
and pneumonia (n=2). Serious adverse events suspected to
be related to study medication were reported in 14
patients (19.4%: DLBCL, n=3; MCL, n=9; FL, n=2), and
were all grade 3/4. Overall, 18 patients died, including
eight on treatment (occurring ≤30 days after study drug
discontinuation): seven due to underlying DLBCL (n=6)
and MCL (n=1), and one in the DLBCL cohort due to gas-
trointestinal hemorrhage suspected to be related to the
study drug.
Exploratory analysis
Biomarkers were assessed using baseline archival tumor
samples from 52 patients (72.2%) and fresh tumor sam-
ples from one patient (1.4%); all but one of the archival
tumor samples were derived from the primary tumor. Of
the patients with evaluable PI3KCA mutation status (19
with DLBCL, 11 with MCL, and 18 with FL) or PTEN
mutation status (19 with DLBCL, 11 with MCL, and 17
with FL), none had mutations in PI3KCA or PTEN (Online
Supplementary Table S2). Loss of PTEN expression was
evaluable in 20, 12, and 20 patients with DLBCL, MCL,
and FL, respectively; none of these patients met the crite-
ria for loss of PTEN expression.
Discussion
Buparlisib elicited tumor reduction in patients with
relapsed or refractory NHL; patients in all cohorts had
reductions in tumor size, and the median progression-free
survival was 1.8, 11.3, and 9.8 months in the DLBCL,
MCL, and FL cohorts, respectively. The median overall
survival, although not yet matured, was 5.2 months (95%
CI: 3.1-not estimable) for the DLBCL cohort and was not
reached for the MCL and FL cohorts. 
The PI3K/mTOR pathway is frequently activated in
NHL and plays an important role in the pathogenesis of
this disease.14 However, mutations in key components of
the PI3K pathway, such as PIK3CA, seem infrequent in
this condition.10,36 Consistently, no PIK3CA or PTENmuta-
tions were detected in the 42 tumor samples tested for
mutations in this study. Despite previous reports of a
reduction or loss of PTEN expression in approximately
21% of FL,36 37% of DLBCL,11 and 15% of MCL sam-
ples,23,37 no PTEN loss was observed among the 50 tumors
tested in this study, which may be explained by the strin-
gent cut-off used for defining a loss of expression (< 10%
expression by immunohistochemistry). Further investiga-
tion, including a broader evaluation of PI3K activation
markers or multivariate analyses of baseline characteris-
tics, would be needed to identify subpopulations of
patients who might respond to buparlisib. 
Preclinical models suggest that all PI3K isoforms (PI3Kα,
PI3Kb, and PI3Kd) are expressed in leukocytes,38 but that
their relative levels of expression vary in NHL according to
disease stage.23 Specific PI3K isoform ratios are associated
with relapse and have been implicated in resistance to
PI3Kd inhibitors, but not PI3Kα/PI3Kd inhibitors.23
Previous studies on PI3K inhibitors that specifically tar-
get one or two PI3K isoforms have met with some success
in indolent NHL (overall response rate of 65% with
duvelisib),39 in FL and in MCL (overall response rates of
45% and 40%, respectively, with idelalisib),40,41 but not in
DLBCL (overall response rate of 0% with rigosertib).42
However, improved long-term outcomes (e.g., progres-
sion-free survival) with these agents have been limited in
patients with relapsed or refractory disease; for example,
the median progression-free survival of patients treated
with idelalisib was 3.7 months among those with MCL
and 7.6 to 11 months for patients with indolent NHL (the
majority, 58% - 59%, with FL).20,40,41 Pan-PI3K inhibition
results in similar or higher overall response rates (≤25% in
DLBCL, 83% in MCL, and 20% - 50% in FL),43-45 with
potentially longer progression-free survival. For example,
in a study of the pan-PI3K inhibitor SAR245409, the over-
all response rate was 50% and the median progression-
free survival was not reached after 8 months of follow-up
in patients with relapsed or refractory FL.45 In our study,
patients with FL on treatment with buparlisib had an over-
all response rate of 25.0% and a median progression-free
survival of 9.8 months. Thus, it appears that sustained
inhibition of all PI3K isoforms has some effect on achiev-
ing response, but may have a more pronounced benefit on
long-term outcomes for patients with FL and MCL. In gen-
eral, PI3K inhibitors have a manageable safety profile in
NHL;46-48 however, the European Medicines Agency has
recently opened a review of idelalisib due to new safety
concerns over serious adverse events (mostly infections) in
ongoing clinical trials. 
Buparlisib was generally well tolerated. Hyperglycemia,
although frequently reported, is a known on-target effect
of PI3Kα inhibitors9 and, as in other buparlisib studies,30
was manageable with standard antidiabetic therapy.
Mood disorders have been previously reported in studies
of buparlisib49 owing, in part, to the ability of this drug to
cross the blood-brain barrier.50 For this reason, in this
study, patients with active psychiatric disorders at screen-
ing were excluded, and the patients enrolled were
prospectively followed with self-assessment question-
naires (i.e., GAD-7 and PHQ-9). As in previous studies,
some patients with NHL experienced mood disorders that
were not serious and were manageable with dose reduc-
tion/interruption or treatment with appropriate concomi-
tant medication. In addition, patients developing any of
these adverse events were referred for psychiatric consul-
tation. Loss of appetite and weight (Online Supplementary
Table S3) in patients may compromise quality of life, as
reported in some previous studies.51
Most treatment-related adverse events with buparlisib
were grade 1/2 and could be managed with dose reduction
or interruption until resolution of toxicity. The rates of
grade 3/4 elevations in alanine aminotransferase and
aspartate aminotransferase, pneumonia, and diarrhea
were lower with buparlisib than with a selective PI3Kd
inhibitor in patients with relapsed or refractory NHL.20
Although the overall response rate with buparlisib was
not substantial, the observed progression-free survival in
A. Younes et al.
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this study warrants further evaluation of this agent in
hematologic cancers. Combination of buparlisib with
other treatments (i.e., targeted therapies, monoclonal anti-
CD20 antibodies, checkpoint inhibitors, or standard
chemotherapies) should be considered, particularly for
patients with FL and MCL. 
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